TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05781633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eutidrone etoposide bevacizumab
Description: Eligible patients received a regimen of eutidrone(30mg/m2/d,iv,d1-5,21d/cycle), etoposide(30mg/m2/d,iv,d1-3,21d/cycle), and bevacizumab (10mg/kg,d1,21d/cycle).At least 4 to 6 cycles were administered, and if patients had a response or stable disease, bevacizumab was used as maintenance therapy until disease progression or intolerable toxicity.MRI of the brain with contrast enhancement was performed at baseline and every 6 weeks after enrollment; thereafter, patients with stable disease or a response could be assessed at a reduced frequency to every 9 weeks; central nervous system and noncentral nervous system lesions were assessed according to RANO-BM criteria and RECIST v1.1 criteria until disease progression, respectively.
Study: NCT06120348

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Charge-Balanced, Symmetric Nerve Stimulation
Description: Charge-Balanced, Symmetric Nerve Stimulation device 30 mins once a day for 4weeks(28days) and twice a week from the 5weeks to the 12 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Sham device 30 mins once a day for 4weeks(28days) and twice a week from the 5weeks to the 12 weeks.
Study: NCT05572268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: to evaluate the safety and efficacy of Ansa for the treatment of UTi and control of Ecoli infection
Description: to evaluate the safety and efficacy of Cranmax for the treatment of UTi and control of Ecoli infection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: to evaluate the safety and efficacy of Ansa for the treatment of UTi and control of Ecoli infection
Description: to evaluate the safety and efficacy of Cranmax for the treatment of UTi and control of Ecoli infection
Study: NCT05755074

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation through left arm
Description: Ablation through left arm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation through femoral vein
Description: Ablation through femoral vein
Study: NCT05222763

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-assisted patient education intervention designed according to the self-regulation model
Description: Implementation of patient education with the website created about care and compliance needs in mastectomy patients obtained as a result of qualitative research.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The website where the mastectomy patients handbook
Description: The site where the patient booklet is available as pdf
Study: NCT06339619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: 20mg/kg ivgtt D1 Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 250mg PO QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur
Description: dosing based on body surface area：BSA\<1.25m2,40mg; BSA=1.25～1.5m2,50mg; BSA\>1.5m2, 60mg，PO QD D1-21 Q3W
Study: NCT06048692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefepime 1000 MG
Description: Cefepime is a fourth-generation cephalosporin antibiotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin-sulbactam
Description: Broad-Spectrum Antibiotic
Study: NCT06494527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG002C0106
Description: RG002C0106 is a siRNA drug targeting complement C3 to silence the related gene through the RNA interfering mechanism and inhibit the expression of C3 protein.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RG002C0106
Description: RG002C0106 is a siRNA drug targeting complement C3 to silence the related gene through the RNA interfering mechanism and inhibit the expression of C3 protein.
Study: NCT05155241

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online health promotion video
Description: Participants will watch an online health promotion video tailored to their current stage of change related to seasonal influenza vaccination uptake once every two weeks for four times (at week 0, 2, 4, and 6)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control (same online health promotion video)
Description: Participants will watch a same online video providing general advices related to seasonal influenza vaccination at week 0, 2, 4, and 6
Study: NCT05486117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delgocitinib
Description: Cream for topical application 20 mg/g
Study: NCT05580419

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4PCP Course
Description: 4PCP is a training framework for the management of chronic pain and gives practitioners lasting knowledge on how to better care for chronic pain patients.
Study: NCT05658874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multimodal Bundle Drugs
Description: multimodal pain therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Operative Cystoscopy
Description: Evaluate bladder and treat Hunner lesions with kenalog or fulguration as appropriate

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral health consultation/therapy
Description: Patient to see behavioral health/psychiatric care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor physical therapy
Description: Patient to have evaluation and treatment by a trained pelvic floor physical therapist

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Urogynecologic care
Description: Usual care from practicing academic Urogynecologist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bladder Instillation
Description: Intravesical lidocaine, heparin, sodium bicarb, Kenalog, gentamicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal estrogen
Description: Topical vaginal estradiol application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methenamine
Description: UTI prevention/bladder therapeutic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline/Gabapentin
Description: Part of multimodal pain therapy
Study: NCT04663100

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-reported outcome measure
Description: Participants will complete a patient-reported outcome measure for their oral anticancer agent at two timepoints over 2 months, to assess patient symptoms and adherence to their oral anticancer agent.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Medication Review
Description: Following the first patient-reported outcome measure, participants will be contacted by the community pharmacist for a Comprehensive Medication Review (CMR) for their chronic medications. A follow-up CMR will take place after the second patient-reported outcome measure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist communication
Description: Throughout the study, the oncology and community pharmacists will communicate about medications through the electronic medical record.
Study: NCT04982146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: 20mg per mL of total tumor volume calculated, administered percutaneously
Study: NCT05814081

Intervention type: PROCEDURE
Intervention: Position/Ventilation
Description: Positioning and ventilation mode adjustments were made to the patients.

Intervention type: PROCEDURE
Intervention: Position/Ventilation
Description: Positioning and ventilation mode adjustments were made to the patients.

Intervention type: PROCEDURE
Intervention: Position/Ventilation
Description: Positioning and ventilation mode adjustments were made to the patients.

Intervention type: PROCEDURE
Intervention: Position/Ventilation
Description: Positioning and ventilation mode adjustments were made to the patients.
Study: NCT06298019

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KYV-101
Description: The investigational product, KYV-101, is an autologous CD19-targeted CAR T-cell immunotherapy.
Study: NCT06403865

Intervention type: DRUG
Intervention: Cabotegravir, Rilpivirine Drug Combination
Description: Treatment switch to CAB+RPV LA
Study: NCT05722600

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grape juice
Description: Hardaliye (grape juice) is a fermented, traditional non-alcoholic beverage made from fresh grapes. It is mainly produced by the fermentation of grapes, sour cherry leaves and mustard seeds. Hardaliye was purchased from traditional producers in Turkey. Hardaliye Group consumed 250 ml/day of hardaliye (grape juice) for 28 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Placebo drink has carbohydrate, energy and sensory properties similar to hardaliye. Placebo Group consumed 250 ml/day of placebo drink
Study: NCT06461208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encapsulated FMT
Description: Encapsulated Faecal Microbiota Transplant

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo product contains microcrystalline methylcellulose. It is supplied as a size 0, Swedish Orange Delayed-Release capsule (DRCap) and provides a complete match with regards to the appearance (e.g., dimensions, colour) to the FMT capsules.
Study: NCT06021977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib was specifically designed to deliver complete and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity.
Study: NCT05881096

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: START - Startle Adjuvant Rehabilitation Therapy
Description: Application of startling acoustic stimuli during practice of movement task

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Description: Practice of movement task without START
Study: NCT05587088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Petiveria Alliacea Preparation
Description: Petiveria Alliacea Preparation in pill

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Petiveria Alliacea Preparation
Description: Petiveria Alliacea Preparation in pill

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Petiveria Alliacea Preparation
Description: Petiveria Alliacea Preparation in pill

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in pill
Study: NCT05047406

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bacillus clausii Probiotic liquid
Description: mini bottles for oral administration containing 2 million spores of Bacillus clausii
Study: NCT05140733

Intervention type: PROCEDURE
Intervention: lumbar foraminal decompression
Description: lumbar foraminal decompression with endoscopic instruments.

Intervention type: PROCEDURE
Intervention: Fusion surgery
Description: Fusion surgery for patients with foraminal stenosis
Study: NCT06372028

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous vagus nerve stimulation (tVNS)
Description: tVNS allows the non-invasive stimulation of the Vagus Nerve by delivering electrical pulses to the sensory afferent fibers of the auricular, thick-myelinated, branch of the vagus nerve in the outer ear. TVNS seems to engage the same neural pathways of invasive VNS methods and may provide a novel, bottom-up NIBS method to enhance gamma-aminobutyric acid and Noradrenaline levels, which play a pivotal role in brain plasticity. The stimulation will be performed by using a Conformite Europeenne (CE) marked tVNS device tVNS®E (tVNS, technologies Gesellschaft mit beschränkter Haftung (GMBH), Erlangen, Germany). It consists in a programmable stimulation unit connected to two titan ear electrodes that are mounted on a gel frame, allowing to generate and transfer electric impulses from the stimulation unit to the surface of the skin, where the electrodes are applied.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcutaneous vagus nerve stimulation (tVNS)
Description: tVNS allows the non-invasive stimulation of the Vagus Nerve by delivering electrical pulses to the sensory afferent fibers of the auricular, thick-myelinated, branch of the vagus nerve in the outer ear. TVNS seems to engage the same neural pathways of invasive VNS methods and may provide a novel, bottom-up NIBS method to enhance gamma-aminobutyric acid and Noradrenaline levels, which play a pivotal role in brain plasticity. The stimulation will be performed by using a Conformite Europeenne (CE) marked tVNS device tVNS®E (tVNS, technologies Gesellschaft mit beschränkter Haftung (GMBH), Erlangen, Germany). It consists in a programmable stimulation unit connected to two titan ear electrodes that are mounted on a gel frame, allowing to generate and transfer electric impulses from the stimulation unit to the surface of the skin, where the electrodes are applied.
Study: NCT05437198

Intervention type: OTHER
Intervention: collection of human exhalation
Description: the collection of the exhalation will be carried out with a non-invasive device manufactured by a Chinese company.~The collection of exhalation consists of the subject inhaling through the nose and exhaling gently through the mouth through a plastic straw for a time set at 5 min in the device

Intervention type: OTHER
Intervention: collection of human exhalation
Description: the collection of the exhalation will be carried out with a non-invasive device manufactured by a Chinese company.~The collection of exhalation consists of the subject inhaling through the nose and exhaling gently through the mouth through a plastic straw for a time set at 5 min in the device
Study: NCT04719767

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: visual laryngeal mask
Description: After anesthesia induction, visual laryngeal mask airway was placed in the visual group and tracheal intubation was guided under visual conditions. In the non-visual group, laryngeal mask airway was inserted, after clinical judgment of good counterpoint of the laryngeal mask, endotracheal intubation was inserted blindly through LMA. Selection of laryngeal mask airway (LMA) model: the ideal body weight of the patient was calculated.
Study: NCT04869280

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study: NCT05761223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase Ia dose-escalation part of FB849 Monotherapy
Description: At a given level dose once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase Ib dose-expansion of FB849 monotherapy
Description: At recommended dose for expansion cohort once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase IIb dose-escalation part of FB849 in Combination with Pembrolizumab
Description: At recommended dose for expansion cohort once daily in combination with pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type A cancer)
Description: At recommended dose for expansion cohort once daily in combination with pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type B cancer)
Description: At recommended dose for expansion cohort once daily in combination with pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type C cancer)
Description: At recommended dose for expansion cohort once daily in combination with pembrolizumab
Study: NCT05860023

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Individuals in the experimental group will be asked to perform aerobic exercise or pelvic floor muscle strengthening exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Individuals in the experimental group will be asked to perform aerobic exercise or pelvic floor muscle strengthening exercises.
Study: NCT05103696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Besylate
Description: Remazolam 7mg for the first time (push time 1min), 2.5mg can be added after 2min according to MOAA/S score, no more than 5 times within 15min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etomidate combined with propofol
Description: Etomidate 0.1mg/kg+1% propofol 0.5mg/kg for the first time ,etomidate0.05mg/kg+ 1% propofol 0.25 mg/kg can be added according to MOAA/S score
Study: NCT04497909

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Mindfulness online training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Mindfulness online training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Mindfulness online training
Study: NCT06137222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tenex TXB MicroTip Ultrasound system plus SOC
Description: Subcutaneous sharp debridement of the index DFU using standard technique (curettage or sharp blade debridement) plus wound care offloading. The index foot ulcer will be dressed with collagen alginate, gauze and roll gauze. Each subject will return for weekly wound assessment, serial sharp debridement if needed and repeat dressing changes. This care will occur for a duration of 12 weeks or until wound closure is confirmed. Defined as standard of care (SOC).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care for diabetic foot ulcer
Description: Use of standard of care for the treatment of a diabetic foot ulcer
Study: NCT05579158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile application and wearable device
Description: Mobile application-supported nutritional counseling includes education, monitoring, interaction, and physical activity

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile application and wearable device
Description: Mobile application-supported nutritional counseling includes education, monitoring, interaction, and physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Description: Time-restricted eating (an 8-hour period (from 10 a.m. to 6 p.m.) each day)
Study: NCT04830956

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FID123238
Description: Lubricant applied to the ocular surface

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FID123238
Description: Lubricant applied to the ocular surface

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FID123238
Description: Lubricant applied to the ocular surface

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FID123238
Description: Lubricant applied to the ocular surface

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FID123238
Description: Lubricant applied to the ocular surface

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systane Hydration
Description: Drops applied to the ocular surface

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systane Hydration
Description: Drops applied to the ocular surface

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systane Hydration
Description: Drops applied to the ocular surface

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systane Hydration
Description: Drops applied to the ocular surface

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systane Hydration
Description: Drops applied to the ocular surface
Study: NCT04668586

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holmium:YAG laser machine
Description: Ureteroscopy with Holmium:YAG laser lithotripsy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thulium Fiber laser machine
Description: Ureteroscopy with Thulium Fiber laser lithotripsy
Study: NCT06389019

Intervention type: OTHER
Intervention: Deep learning system for prognostication prediction in bladder cancer
Description: develop and validate a deep learning system for prognostication prediction in bladder cancer based on CT radiomics and whole slide images.
Study: NCT06248931

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproic acid
Description: The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients will receive valproate 500-1000 mg daily and Acetaminophen 500-1000 mg only in acute migraine attacks for 3 months. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of valproate was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate 50 MG
Description: The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients will receive topiramate 50-100 mg daily and Acetaminophen 500-1000 mg only in acute migraine attacks for 3 months. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of topiramate was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
Study: NCT05506501

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: unilateral epidural anesthesia
Description: Forty patients with low ejection fraction (30-40%) will do elective insertion of nail tibia for fixation of fracture shaft tibia using unilateral epidural anesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided femoro/ sciatic nerve block
Description: Forty patients with low ejection fraction (30-40%) will do elective insertion of nail tibia for fixation of fracture shaft tibia by femoral/sciatic nerve block using ultrasound guidance.